SCHEMBL4161909

SCHEMBL4161909

N=C(N)Nc1cccc(CN2CCOCC2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.57
ALDH1A1 P00352 5/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
NOS1 P29475 1/20 0.55
LMNA P02545 2/20 0.52
KDM1A O60341 1/20 0.52
RCOR1 Q9UKL0 1/20 0.52
HIF1A Q16665 2/20 0.51
EPAS1 Q99814 2/20 0.51
HTT P42858 3/20 0.49
KDM4E B2RXH2 1/20 0.49
HPGD P15428 1/20 0.49
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
TP53 P04637 2/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
AURKA O14965 1/20 0.46
RPS6KB1 P23443 1/20 0.46
KCNH2 Q12809 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL7865761 0.85 SMN1; SMN2 (0.59) NCF1ALDH1A1SMN1; SMN2NOS1LMNA
SCHEMBL13883597 0.84 SMN1; SMN2 (0.58) NCF1ALDH1A1SMN1; SMN2NOS1LMNA
SCHEMBL3975661 0.83 HRH3 (0.59) SMN1; SMN2NOS1HIF1AEPAS1HTT
SCHEMBL13946389 0.81 NCF1 (0.65) NCF1ALDH1A1SMN1; SMN2NOS1LMNA
SCHEMBL30577399 0.81 SMN1; SMN2 (0.63) NCF1ALDH1A1SMN1; SMN2NOS1LMNA
SCHEMBL17754101 0.81 SMN1; SMN2 (0.63) NCF1ALDH1A1SMN1; SMN2NOS1LMNA
Hydrochloric Acid SCHEMBL4192881 0.80 NCF1 (0.63) NCF1ALDH1A1SMN1; SMN2NOS1LMNA
SCHEMBL411747 0.79 SMN1; SMN2 (0.53) NCF1ALDH1A1SMN1; SMN2NOS1LMNA
SCHEMBL4367879 0.79 NCF1 (0.60) NCF1ALDH1A1SMN1; SMN2NOS1LMNA
SCHEMBL19652068 0.78 ACKR3 (0.61) ALDH1A1SMN1; SMN2LMNAKDM1ARCOR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP disclosed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 NCF1 1983/4885ALDH1A1 2743/4885SMN1; SMN2 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.